The G196A polymorphism of the brain-derived neurotrophic factor gene and the antidepressant effect of milnacipran and fluvoxamine. - Wikidata - awgldk - TriplyDB

The G196A polymorphism of the brain-derived neurotrophic factor gene and the antidepressant effect of milnacipran and fluvoxamine.

The G196A polymorphism of the brain-derived neurotrophic factor gene and the antidepressant effect of milnacipran and fluvoxamine.

http://www.wikidata.org/entity/Q48375775

about

From pharmacogenetics to pharmacogenomics: the way toward the personalization of antidepressant treatment Association between BDNF gene polymorphisms and serotonergic activity using loudness dependence of auditory evoked potentials in healthy subjects Ethanol-BDNF interactions: still more questions than answers.Improving the prediction of treatment response in depression: integration of clinical, cognitive, psychophysiological, neuroimaging, and genetic measures.Association between serotonin transporter polymorphisms (5-HTTLPR) and the MADRS Dysphoria, Retardation, and Vegetative Subscale scores in the treatment of depression BDNF val66met polymorphism, white matter abnormalities and remission of geriatric depression.Pharmacogenetics of antidepressant response.BDNF Val66Met genotype and 6-month remission rates in late-life depression Understanding the pharmacogenetics of selective serotonin reuptake inhibitors.The BDNF gene Val66Met polymorphism as a modifier of psychiatric disorder susceptibility: progress and controversy.Effects of BDNF polymorphisms on antidepressant action.Possible associations of NTRK2 polymorphisms with antidepressant treatment outcome: findings from an extended tag SNP approach.Review and meta-analysis of antidepressant pharmacogenetic findings in major depressive disorder.Pharmacogenetics of antidepressants The promise and reality of pharmacogenetics in psychiatry Neurotrophins role in depression neurobiology: a review of basic and clinical evidence.Association study of a brain-derived neurotrophic-factor polymorphism and short-term antidepressant response in major depressive disorders.Pharmacogenomics with antidepressants in the STAR*D study.Brain-derived neurotrophic factor and antidepressant action: another piece of evidence from pharmacogenetics.BDNF gene: functional Val66Met polymorphism in mood disorders and schizophrenia.Personalized medicine for depression: can we match patients with treatments?Pharmacogenetics of antidepressant drugs: current clinical practice and future directions.Pharmacogenetics of antidepressant drugs: an update after almost 20 years of research.Brain-derived neurotrophic factor Val66Met polymorphism association with antidepressant efficacy: a systematic review and meta-analysis.Pharmacogenetics of major depressive disorder: top genes and pathways toward clinical applications.BDNF/TRKB/P75NTR polymorphisms and their consequences on antidepressant efficacy in depressed patients.Candidate-gene association study searching for genetic factors involved in migraine chronification.Val66Met BDNF genotypes in melancholic depression: effects on brain structure and treatment outcome.Progress in Elucidating Biomarkers of Antidepressant Pharmacological Treatment Response: A Systematic Review and Meta-analysis of the Last 15 Years.Association of brain-derived neurotrophic factor valine to methionine polymorphism with sexual dysfunction following selective serotonin reuptake inhibitor treatment in female patients with major depressive disorder.Imaging genetics: implications for research on variable antidepressant drug response.Genes involved in neuroplasticity and stressful life events act on the short-term response to antidepressant treatment: a complex interplay between genetics and environment.Further evidence supporting the influence of brain-derived neurotrophic factor on the outcome of bipolar depression: independent effect of brain-derived neurotrophic factor and harm avoidance.General and comparative efficacy and effectiveness of antidepressants in the acute treatment of depressive disorders: a report by the WPA section of pharmacopsychiatry.

P2860

Q27015830-FE185289-2D36-4549-B62E-8B0FB42A7EFD Q28486109-502B5F99-10B3-489F-920D-E2AEB5918ED4 Q30490427-DA279F68-1D69-481A-800C-053033A4EDB6 Q33404025-1865E402-BF4E-4386-87DE-A9A13CC45D44 Q33806771-D5F284FC-7B93-4EA5-9586-1B3CB6A889B2 Q33992471-61EE88AB-5EA6-498C-AEA1-A022D67C84C7 Q34155796-A828FFA5-65F8-46BB-A40C-21287A47E8C9 Q34233144-A13878E5-2CF8-4BEA-946B-7C0BE0D87E9D Q34424865-F632531F-CE44-4309-A25A-5396CCFA7191 Q34469404-440CA134-94BA-47DF-A362-D233B22FFC17 Q34497530-30AAA674-DF8A-40DB-A1F9-C7F736E6E450 Q34764142-11D06C76-F118-45BD-86AD-189C5768F0F1 Q34871885-C4BA84DB-54FF-45B0-AE71-A4E7DD272A60 Q35026088-6C5C8610-03A8-4956-A085-8860E87C84E9 Q35226451-DC125A36-FCBC-46CF-8858-17DC4EDD917F Q35687024-5B730CED-651F-4409-B2C0-22A027073A27 Q36441426-20C0B27E-6C4B-4414-A724-3882B39C3E10 Q37205961-FE51A829-18E6-4377-B7E1-0A7D36E618C1 Q37264563-97B9B358-5850-4D7E-BB43-EB75B2B3205B Q37329157-B59779A4-BF92-4DD9-A2EB-BA2B72B0BD33 Q37789098-F58B2BD1-5098-4B6B-AEA6-135E8DD0E849 Q37989490-163936BD-DDC5-4FF9-A759-64738911B7CF Q38121519-04706306-A642-40C3-96AB-444AE55B5C33 Q38251192-CFD8366A-3798-42C5-BD4E-7D8964A3E8CE Q38484370-331FBE62-FA1C-40F9-9CC6-5CBA5730E230 Q38540142-BBFB9C71-DBAF-4351-B4EE-992575760619 Q39138048-2B5FB780-819D-47AE-84FA-CBF46C43A5E6 Q46654662-D920EC1C-BBDE-4871-BE58-53DBC18E0757 Q47666907-FC47E435-1C53-48A9-B7BE-28969A8B7A64 Q47966052-6314AB73-3B89-477E-8EDA-66670EAA0C2B Q48148747-1BC33A8E-8D34-4484-BC58-27600B22FA83 Q48224587-1B180F57-F480-43AD-95A3-E51E32027695 Q48315286-65E5C6FD-481E-40DC-98E7-CE1A3FCB3A59 Q51509688-BC9369D7-D2A9-4072-865A-A79710C24867

P2860

The G196A polymorphism of the brain-derived neurotrophic factor gene and the antidepressant effect of milnacipran and fluvoxamine.

http://www.wikidata.org/entity/Q48375775

description

2006 nî lūn-bûn

@nan

2006年の論文

@ja

2006年学术文章

@wuu

2006年学术文章

@zh

2006年学术文章

@zh-cn

2006年学术文章

@zh-hans

2006年学术文章

@zh-my

2006年学术文章

@zh-sg

2006年學術文章

@yue

2006年學術文章

@zh-hant

name

The G196A polymorphism of the ...... f milnacipran and fluvoxamine.

@en

The G196A polymorphism of the ...... f milnacipran and fluvoxamine.

@nl

type

label

The G196A polymorphism of the ...... f milnacipran and fluvoxamine.

@en

The G196A polymorphism of the ...... f milnacipran and fluvoxamine.

@nl

prefLabel

The G196A polymorphism of the ...... f milnacipran and fluvoxamine.

@en

The G196A polymorphism of the ...... f milnacipran and fluvoxamine.

@nl

P1433

Q48375775-411BDD1A-10F7-4C04-9685-7597AA34D7C2

P1476

Q48375775-959A3C8D-8D64-4C4C-8616-62135E450A88

P2093

Q48375775-1D929769-B574-4E83-9CB3-8977EEBCB0E5

Q48375775-236DE099-94F9-4DE1-B624-B3DB31DB8EC0

Q48375775-37107092-1590-49E9-8C69-46238C671BED

Q48375775-74250E85-1F9F-497F-9B07-4C9DD2852F2B

Q48375775-8551A511-F316-449D-8DEB-99047AC960DD

Q48375775-D3386C41-48C8-4AE7-91E6-D6FEB1D138A6

Q48375775-F08BAD8E-EE3F-4227-871D-AD3320DEFF59

P2860

Q48375775-0637D035-5D56-4E37-BD5E-F70AE9B2DCD6

Q48375775-107EF798-487B-4F3A-AD65-38D27D93D989

Q48375775-22047A84-DC4F-4267-8B74-39AA665E6FE3

Q48375775-23938601-1F34-4026-BE37-C4C67F1BC5D3

Q48375775-36398255-6783-461B-8DEE-94BF69AF7AD3

Q48375775-3AA1BAB5-72FF-4C78-AB88-88A72F5260A2

Q48375775-4A6C5A45-7623-4B26-B1E1-D7FEEAEA1658

Q48375775-4F3DAC5B-2435-4052-92DE-867D3E002189

Q48375775-648D92BF-EFCA-42EF-99BE-3F4A9DBA7131

Q48375775-74785521-EEC4-486E-985C-671F634B6534

P304

Q48375775-A15A5916-1EA8-43ED-916D-068F238E4794

P31

Q48375775-0C67BA34-344E-4966-A4E8-546315682246

P356

Q48375775-318C168F-A66C-456C-93B2-E443ED01ECC9

P407

Q48375775-E488B1B5-3D61-4559-94C9-773F6950BF99

P433

Q48375775-ECAAA76C-6DAB-422F-B195-FCD55805517F

P478

Q48375775-48EEE3E8-C2C7-4ADD-9742-04346C5C9270

P50

Q48375775-899AD328-2C97-4C17-8286-DF13331192AA

P577

Q48375775-FDF65F1E-C599-4BA0-BAB8-0D19C9057C8B

P698

Q48375775-A2904114-5D8E-4C4B-A595-F9F1038BE015

P356

0269881106072192

P1433

Journal of Psychopharmacology

P1476

The G196A polymorphism of the ...... f milnacipran and fluvoxamine.

@en

P2093

Hisashi Higuchi

http://www.w3.org/2001/XMLSchema#string

Hitoshi Takahashi

http://www.w3.org/2001/XMLSchema#string

Kazuyuki Inoue

http://www.w3.org/2001/XMLSchema#string

Keizo Yoshida

http://www.w3.org/2001/XMLSchema#string

Kunihiko Itoh

http://www.w3.org/2001/XMLSchema#string

Mitsuhiro Kamata

http://www.w3.org/2001/XMLSchema#string

Toshio Suzuki

http://www.w3.org/2001/XMLSchema#string

P2860

Molecular heterosis: a review

A new depression scale designed to be sensitive to change

The BDNF val66met polymorphism affects activity-dependent secretion of BDNF and human memory and hippocampal function

Stress-induced changes in cerebral metabolites, hippocampal volume, and cell proliferation are prevented by antidepressant treatment with tianeptine.

Prefrontal cortical-amygdalar metabolism in major depression.

Therapeutic drug monitoring of antidepressants: cost implications and relevance to clinical practice.

Pharmacogenetics of psychotropic drug response.

The relationship between antidepressant response and tricyclic antidepressant plasma concentrations. A retrospective analysis of the literature using logistic regression analysis.

Dissociating executive functions of the prefrontal cortex.

Exercise, antidepressant medications, and enhanced brain derived neurotrophic factor expression.

P304

650-656

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1177/0269881106072192

http://www.w3.org/2001/XMLSchema#string

P407

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

21

http://www.w3.org/2001/XMLSchema#string

P50

P577

2006-11-08T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

17092970

http://www.w3.org/2001/XMLSchema#string